Intelligent Tissue Group has launched its Intelligent Clinical trials facility to help assess the effectiveness and safety of potential new treatments.
The pharma giant and the clinical-stage drug developer will join on a pilot study investigating a candidate’s potential in overcoming resistance of a cancer drug.
The company's Spectus and Percepta platforms offer features to help researchers meet challenges associated with working and collaborating in the pandemic.
The technology combines predictive analytics and commercial services to help pharma firms and partners maximize drug discovery and development efforts.
This month's spotlight on new hires, promotions and company acquisitions involves Elligo Health Research, PPD, Pfizer, Covance and other industry firms.
The federal agency continues to aid drug developers, trial teams and the public with advice and actions related to the virus behind the global pandemic.
A leader with the industry association discusses the surging interest in harnessing artificial intelligence to advance various treatments and therapies.
The agency continues to offer advice related to drug development and clinical research during the pandemic, and take action against those falling out of line.
A representative of the research and development firm offers perspective on how the industry has shifted in recent years, thanks to a number of forces.
A research team including MIT, Harvard and Stanford researchers has raised $20m in seed funding for their effort to map out immune cells with machine learning.
A representative of the life-sciences consulting firm outlines how the federal agency has reacted to the COVID-19 pandemic, and how it might advise the industry going forward.
The pharmaceutical analysis firm is continuing its contract analytical laboratory services running, with changes designed to keep people and products safe.
Organ-on-a-chip systems are poised to revolutionize drug development in many ways, say researchers advancing the technology, which could support gender-specific medicine, among other use cases.
Trinity’s acquisition of Bell Canyon aims to create an integrated data management offering that will enable all members of a development project to gain access to ‘a single version of truth.’
CAS collates the world’s largest collection of formulations – a ‘one-stop-shop’ that will help formulators innovate faster and solve problems, ultimately reducing drug development timelines, says project lead.
To improve patient safety and reduce risk, Elsevier is developing an improved drug-drug interaction risk calculator in collaboration with several pharma partners, including Boehringer Ingelheim, Eli Lilly, and Servier.
As summer heated up, the pharmaceutical industry saw major developments in preclinical models from new software to 3D-printed tissue, all in the name of drug development.
Regulatory actions by the FDA have enabled rare disease drug development to become a compelling space with orphan drug designations and approvals trending upward, says life sciences industry attorney.
More than half of new drug approvals last year were for rare diseases – which face long cycle times and other operational challenges that are necessitating the rapid adoption of new solutions, per a recent Tufts report.
Scientific advances and regulatory incentives are driving the use of genetics in drug development, though the industry’s ability to perform wide-scale testing has outpaced its understanding of the results, the misinterpretation of which can have “disastrous”...
Improving the prognostic value of early phase data is among one of several ways to increase the probability of successes in drug development, a process which has become more expensive as failure rates have risen, says an industry expert.
Live updates from the DIA Global Annual Meeting 2019 in San Diego as industry leaders from over 50 countries and 400 companies discuss the progress and innovations in drug product development.
A new 3D-printed, all-liquid device automates complex chemical reactions on demand – enabling drug screening with limited materials, such as patient biopsies, says researcher.
In which areas is artificial intelligence most mature? What are the challenges to widespread adoption? Tufts and DIA recently teamed up to explore these questions.
New this year to the discussion at DIA is the conversation around data ownership, as the industry continues to face a deluge of information from more sources than ever.
As regulators work to advance the modern clinical trial, the risk-averse clinical research industry is falling behind in the race to bring new therapies to patients, says an industry expert, echoing the former FDA commissioner’s calls for innovation.
Aptar Group acquires two pharmaceutical services companies, Nanopharm and Gateway Analytical, to boost its analytical, testing, and development capabilities.
Natural history studies provide researchers with a better understanding of a disease’s progression, supporting clinical trial design, among other benefits, say industry experts commenting on the FDA’s new draft guidance.
Researchers describe a technique to quantify a person’s “immune age,” information which could help design and analyze clinical trials – improving the drug development process, among other “impressive” possibilities, says industry expert.
